IL-17 promoted metastasis of non-small-cell lung cancer cells

Immunology Letters

Volumn 148, Issue 2, 2012, Pages 144-150

  Li, Qinchuan ^a   Han, Yang ^a   Fei, Guangru ^a   Guo, Zhongliang ^a   Ren, Tao ^a   Liu, Zhongmin ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

IL 17, IL 6; Lung cancer; Metastasis; NSCLC

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 6; MESSENGER RNA; STAT3 PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR VOLUME;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTORS, INTERLEUKIN-17; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84869845842     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.10.011     Document Type: Article

References (32)

1. Govindan R., Bogart J., Vokes E.E. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol 2008, 3:917-928.
2. Chen X., Wan J., Liu J., Xie W., Diao X., Xu J., et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010, 69:348-354.
3. Brundage M.D., Davies D., Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002, 122:1037-1057.
4. Carmi Y., Rinott G., Dotan S., Elkabets M., Rider P., Voronov E., et al. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol 2011, 186:3462-3471.
5. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007, 25:821-852.
6. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
7. Kolls J.K., Lindén A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
8. Bettelli E., Oukka M., Kuchroo V.K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, 8:345-350.
9. Martin-Orozco N., Dong C. The IL-17/IL-23 axis of inflammation in cancer: friend or foe?. Curr Opin Investig Drugs 2009, 10:543-549.
10. Ngiow S.F., Smyth M.J., Teng M.W. Does IL-17 suppress tumor growth. Blood 2010, 115:2554-2555.
11. Ji Y., Zhang W. Th17 cells: positive or negative role in tumor. Cancer Immunol Immunother 2010, 59:979-987.
12. Benchetrit F., Ciree A., Vives V., Warnier G., Gey A., Sautès-Fridman C., et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002, 99:2114-2121.
13. Hirahara N., Nio Y., Sasaki S., Minari Y., Takamura M., Iguchi C., et al. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 2001, 61:79-89.
14. Numasaki M., Fukushi J., Ono M., Narula S.K., Zavodny P.J., Kudo T., et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101:2620-2627.
15. Kryczek I., Wei S., Szeliga W., Vatan L., Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009, 114:357-359.
16. Numasaki M., Watanabe M., Suzuki T., Takahashi H., Nakamura A., McAllister F., et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005, 175:6177-6189.
17. Chen X., Xie Q., Cheng X., Diao X., Cheng Y., Liu J., et al. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci 2010, 101:2384-2390.
18. Avigan D., Vasir B., Gong J., Borges V., Wu Z., Uhl L., et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004, 10:4699-4708.
19. Ren T., Wen Z.K., Liu Z.M., Qian C., Liang Y.J., Jin M.L., et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients. Cancer Invest 2008, 26:448-455.
20. Ren T., Xu L., Jiao S., Wang Y., Cai Y., Liang Y., et al. TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res 2009, 15:623-630.
21. Deodhar S.D., James K., Chiang T., Edinger M., Barna B.P. Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res 1982, 42:5084-5088.
22. Ogura H., Murakami M., Okuyama Y., Tsuruoka M., Kitabayashi C., Kanamoto M., et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008, 29:628-636.
23. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009, 206:1457-1464.
24. Sfanos K.S., Bruno T.C., Maris C.H., Xu L., Thoburn C.J., DeMarzo A.M., et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008, 14:3254-3261.
25. Steiner G.E., Newman M.E., Paikl D., Stix U., Memaran-Dagda N., Lee C., et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003, 56:171-182.
26. Le Gouvello S., Bastuji-Garin S., Aloulou N., Mansour H., Chaumette M.T., Berrehar F., et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008, 57:772-779.
27. Zhang J.P., Yan J., Xu J., Pang X.H., Chen M.S., Li L., et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009, 50:980-989.
28. Zhu X., Mulcahy L.A., Mohammed R.A., Lee A.H., Franks H.A., Kilpatrick L., et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 2008, 10:R95.
29. Miyahara Y., Odunsi K., Chen W., Peng G., Matsuzaki J., Wang R.F. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A 2008, 105:15505-15510.
30. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7:41-51.
31. Zhang X., Yue P., Page B.D., Li T., Zhao W., Namanja A.T., et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 2012, 109:9623-9628.
32. Lavecchia A., Di Giovanni C., Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem 2011, 18:2359-2375.